ライフサイエンスコーパス: 5-aminosalicylic acid

1 nance of remission of mild to moderate UC is 5-aminosalicylic acid.

2 eatment with infliximab (0.36; P = .0005) or 5-aminosalicylic acid (0.44; P < .0001) were associated

3 The 5-aminosalicylic acid (5-ASA) agents and oral steroids r

4 one group treated with the anti-inflammatory 5-aminosalicylic acid (5-ASA) and one group untreated),

5 lial oxygenation, but the PPAR-gamma agonist 5-aminosalicylic acid (5-ASA) functionally replaced Clos

6 y used inflammatory bowel disease (IBD) drug 5-aminosalicylic acid (5-ASA) has been attributed, in pa

7 We recently reported that 5-aminosalicylic acid (5-ASA) inhibits TNFalpha-regulate

8 ilable for inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) is still the key medicatio

9 IL-1-mediated COX-2 gene expression whereas 5-aminosalicylic acid (5-ASA) or indomethacin had no eff

10 NSAIDs) 4-aminophenylacetic acid (4-APAA) or 5-aminosalicylic acid (5-ASA) with peptides, including a

11 and its metabolites, sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA), on components of angiogen

12 dy two strategies for delivering mesalazine (5-aminosalicylic acid, 5-ASA) to the colon were compared

13 ferences in the in vitro response of PPK1 to 5-aminosalicylic acid, a known PPK1 inhibitor, and obser

14 atory drugs (OR, 0.1; 95% CI: 0.03-0.5), and 5-aminosalicylic acid agents (OR, 0.4; 95% CI: 0.2-0.9),

15 f sulfasalazine (SSZ) with its two moieties, 5-aminosalicylic acid (ASA) and sulfapyridine (SP), in p

16 er, and smoking and drug history (mesalamine 5-aminosalicylic acid, azathioprine, and folate).

17 Corticosteroids, 5-aminosalicylic acid derivatives, immunomodulators, and

18 Treatments for inducing remission include 5-aminosalicylic acid drugs and corticosteroids.

19 Treatments for ulcerative colitis include 5-aminosalicylic acid drugs, steroids, and immunosuppres

20 Maintenance treatments include 5-aminosalicylic acid drugs, thiopurines, biologics (eg,

21 Two lanthanide complexes, namely 5-aminosalicylic acid ethylenediaminetetraacetate europi

22 ntal data to predict the release of the drug 5-aminosalicylic acid from polysaccharide-based coatings

23 conventional therapy, once daily therapy for 5-aminosalicylic acid is generally sufficient.

24 Furthermore, a new 5-aminosalicylic acid (mesalamine MMX) has been released

25 Derivatives of 5-aminosalicylic acid (mesalamine) represent a mainstay

26 ssification; and use of sulfasalazine, other 5-aminosalicylic acid preparations, prednisone, cyclospo

27 Surveillance colonoscopy and 5-aminosalicylic acid therapy may mitigate cancer risk,

28 rotective factors colonoscopic surveillance, 5-Aminosalicylic Acid, thiopurines, and smoking was mode

29 fective treatment for mild to moderate UC is 5-aminosalicylic acid, whereas moderate to severe UC can

30 e sensitization of Eu3+ is accomplished with 5-aminosalicylic acid, which provides energy transfer fo